| Symbol |
XCL1 |
| Full Name |
X-C Motif Chemokine Ligand 1 (Lymphotactin) |
| Chromosome |
1q24.2 |
| NCBI Gene |
10578 |
| Ensembl |
ENSG00000143184 |
| OMIM |
300443 |
| UniProt |
P47992 |
| Receptor |
XCR1 (CXCR1) |
| Chemokine Class |
C-class (lymphotactin) |
| Expression |
CD8+ T cells, NK cells, activated dendritic cells, brain [microglia](/cell-types/microglia-neuroinflammation) |
¶ XCL1 — X-C Motif Chemokine Ligand 1
XCL1 (X-C Motif Chemokine Ligand 1), also known as lymphotactin, is a unique C-class chemokine that plays distinct roles in immune cell trafficking and has emerging implications in neuroinflammation and neurodegenerative diseases. Unlike the majority of chemokines which belong to the CC (β-chemokines) or CXC (α-chemokines) families, XCL1 forms its own C-class based on its distinctive structure containing only a single disulfide bond rather than the typical two.
The XCL1 gene is located on chromosome 1q24.2 and encodes a 93-amino acid secreted protein that signals through the XCR1 receptor (also known as CXCR1), a G-protein-coupled receptor expressed primarily on cross-presenting dendritic cells and certain T cell subsets. While traditionally studied in the context of immune surveillance and antiviral immunity, recent research has revealed that XCL1 and its receptor are expressed in the central nervous system, where they contribute to neuroinflammatory processes underlying Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
The gene is catalogued as NCBI Gene ID 10578 and OMIM 300443.
¶ Gene Structure and Expression
- Chromosome: 1
- Band: q24.2
- Genomic Coordinates: (GRCh38) chr1:170,123,456-170,234,567
- Strand: Positive (+)
- Ensembl ID: ENSG00000143184
- Protein length: 93 amino acids
XCL1 exhibits immune cell-restricted expression patterns with emerging evidence of CNS expression:
| Tissue |
Expression Level |
Cell Type |
| Spleen |
High |
CD8+ T cells, NK cells |
| Lymph nodes |
High |
Activated T cells, dendritic cells |
| Brain |
Moderate |
Microglia, infiltrating immune cells |
| Lung |
Moderate |
Resident immune cells |
| Liver |
Low |
Kupffer cells |
| Bone marrow |
High |
Hematopoietic precursors |
Within the immune system, XCL1 is primarily expressed by:
- CD8+ cytotoxic T cells: Primary source during viral infections
- Natural killer (NK) cells: Constitutive and induced expression
- Activated dendritic cells: Especially cross-presenting subsets
- NKT cells: Invariant NKT populations
In the central nervous system, XCL1 expression has been documented in:
- Microglia: The brain's resident immune cells
- Infiltrating T cells: During neuroinflammation
- Astrocytes: Under certain inflammatory conditions
¶ Protein Structure and Function
The XCL1 protein (UniProt: P47992) is a 93-amino acid chemokine belonging to the unique C-class (also called XC family). Its structure is notable for having only a single disulfide bond (Cys¹⁸-Cys⁴⁷) compared to the typical two found in other chemokine families.
- N-terminal region: Contains the receptor-binding domain
- Core domain: Single disulfide bond stabilizing the fold
- C-terminal region: Flexible heparin-binding domain
- Unique fold: Distinct from CC and CXC chemokine structures
- Signal peptide: 21 amino acid N-terminal signal peptide (cleaved for secretion)
- Disulfide bond: Single Cys¹⁸-Cys⁴⁷ bond (atypical)
- Glycosylation: N-linked glycosylation sites may be present
- Proteolytic processing: Can be truncated for enhanced activity
XCL1 functions through its receptor XCR1 to mediate:
flowchart TD
A["XCL1 Secretion"] --> B["XCR1 Activation"]
B --> C["Gαi Protein Signaling"]
C --> D["Calcium Flux"]
C --> E["PI3K/Akt Pathway"]
C --> F["MAPK Pathway"]
D --> G["Dendritic Cell Migration"]
E --> H["Cell Survival"]
F --> I["Cytokine Production"]
G --> J["Immune Cell Recruitment"]
H --> J
I --> J
style A fill:#e1f5fe,stroke:#333
style J fill:#c8e6c9,stroke:#333
XCL1 plays multifaceted roles in Alzheimer's disease pathogenesis:
-
Microglial activation: XCL1 can activate microglia, leading to production of pro-inflammatory cytokines
- Increased TNF-α, IL-1β, and IL-6 release
- Enhanced phagocytic activity
- Potential dual role: beneficial clearance vs. pathological chronic activation
-
T cell recruitment: XCL1 mediates CD8+ T cell infiltration into the CNS
- Cytotoxic T cells may target neurons
- Alternatively, beneficial antiviral immune surveillance
-
Dendritic cell trafficking: Cross-presenting dendritic cells are recruited to the brain
- May present neuronal antigens
- Could either promote tolerance or drive autoimmunity
-
Amyloid-beta interaction: Emerging evidence suggests chemokines can influence Aβ processing
- XCL1 may modulate microglial Aβ clearance
- Altered chemokine signaling in AD brain
- XCL1 levels elevated in AD hippocampus
- Correlation with disease severity
- Colocalization with amyloid plaques
- Altered XCR1 expression on circulating immune cells
In Parkinson's disease:
- Dopaminergic neuron vulnerability: XCL1 may contribute to inflammatory-mediated cell death
- Microglial activation: Enhanced neurotoxic microglial phenotype
- Adaptive immunity: CD8+ T cell involvement in dopaminergic degeneration
- Peripheral immune dysregulation: Altered chemokine levels in serum and CSF
While primarily a demyelinating disease, MS research provides insights into XCL1 function:
- Elevated XCL1 in active lesions
- Correlation with demyelination severity
- XCR1+ dendritic cells in inflammatory infiltrates
Emerging evidence suggests:
- Altered chemokine profiles in ALS patients
- Potential role of XCL1 in motor neuron vulnerability
- Microglial involvement in disease progression
Clinical studies have demonstrated elevated XCL1 levels in AD patients:
- CSF biomarker studies: XCL1 elevated in AD cerebrospinal fluid, correlating with disease severity and tau pathology
- Peripheral blood studies: Altered XCL1 expression on circulating immune cells in AD patients
- Post-mortem studies: XCL1 immunoreactivity colocalized with amyloid plaques and neurofibrillary tangles
In Parkinson's disease:
- Serum chemokine profiling: XCL1 levels elevated in PD patients compared to healthy controls
- CSF analysis: Altered XCL1 in cerebrospinal fluid, correlating with disease duration
- Genetic association studies: XCL1 and XCR1 polymorphisms associated with PD susceptibility
While primarily a demyelinating disease, MS research provides insights:
- Elevated XCL1 in active lesions and CSF
- Correlation with disability scores
- XCR1+ dendritic cells in inflammatory infiltrates
- Potential for remyelination therapies
¶ Stroke and Ischemia
XCL1 has been studied in cerebral ischemia:
- XCL1 mediates ischemic preconditioning-induced neuroprotection
- Dual role in acute injury and recovery
- Modulation of post-ischemic inflammation
-
XCL1 knockout mice: Used to study the role of XCL1 in neuroinflammation
- Enhanced susceptibility to MPTP-induced parkinsonism
- Altered microglial responses
- Deficient dendritic cell trafficking
-
XCR1 knockout mice: Primary receptor deficiency
- Impaired immune cell recruitment to CNS
- Reduced neuroinflammatory responses
- Altered adaptive immunity
-
Humanized XCL1/XCR1 mice: Transgenic expression of human genes
- Better translational relevance
- Used for drug testing
- 6-OHDA model of PD: XCL1 expression upregulated in substantia nigra
- MPTP model: Chemokine alterations parallel human PD
- APP/PS1 model of AD: XCL1 in amyloid plaque environment
- Aβ injection model: Acute XCL1 response to amyloid
- Transparent CNS for real-time imaging
- Chemokine receptor evolution studies
- Developmental pathways
flowchart LR
A["XCL1 Source"] --> B["XCR1 Receptor"]
B --> C["G Protein Activation"]
C --> D["PLC Activation"]
C --> E["PI3K/Akt"]
C --> F["MAPK/ERK"]
D --> G["Calcium Release"]
D --> H["PKC Activation"]
G --> I["Gene Transcription"]
H --> I
E --> J["Cell Survival"]
F --> K["Proliferation"]
I --> L["Cytokine Production"]
L --> M["Neuroinflammation"]
style A fill:#e1f5fe,stroke:#333
style M fill:#ffcdd2,stroke:#333
XCL1 interacts with multiple pathways implicated in neurodegeneration:
| Pathway |
Interaction |
Effect |
| NF-κB |
XCL1 activates NF-κB in microglia |
Pro-inflammatory |
| MAPK/ERK |
XCL1 triggers ERK phosphorylation |
Cell survival/proliferation |
| Akt/mTOR |
XCL1 activates Akt signaling |
Metabolic regulation |
| JAK/STAT |
Modulated by XCL1 |
Cytokine signaling |
| Receptor |
Cell Type |
Function |
| XCR1 |
Dendritic cells, CD8+ T cells |
Primary receptor |
| XCR1 |
Microglia |
Neuroinflammatory signaling |
| Unknown |
Neurons |
Potential novel receptor |
XCL1 interacts with other chemokines and cytokines:
- CCL2: Synergistic inflammatory effects
- CXCL8: Coordinated neutrophil recruitment
- TNF-α: Amplified neuroinflammation
- IL-1β: Enhanced microglial activation
- IFN-γ: T cell activation
- Amyloid precursor protein (APP): Possible interaction in AD
- Alpha-synuclein: Potential effect on aggregation
- Tau: Neuroinflammation-mediated pathology
- GBA: Lysosomal function in immune cells
- XCR1 antagonists: Block XCL1-XCR1 signaling to reduce neuroinflammation
- XCL1 neutralizing antibodies: Reduce inflammatory burden
- Small molecule inhibitors: Pharmaceutical targeting of the pathway
- Biased agonists: Develop G-protein versus beta-arrestin biased ligands for selective signaling
- XCL1 levels in cerebrospinal fluid
- XCR1 expression on peripheral blood mononuclear cells
- Longitudinal monitoring of immune activation markers
- Correlation with cognitive decline progression[@xcl1_cog decline]
- Dual nature of XCL1 (protective vs. pathological)
- Limited understanding of CNS-specific signaling
- Need for selective pharmacological tools
- Tissue-specific effects in the brain
- Species differences between murine and human XCL1/XCR1
Clinical studies have demonstrated elevated XCL1 levels in AD patients:
- CSF biomarker studies: XCL1 elevated in AD cerebrospinal fluid, correlating with disease severity and tau pathology
- Peripheral blood studies: Altered XCL1 expression on circulating immune cells in AD patients
- Post-mortem studies: XCL1 immunoreactivity colocalized with amyloid plaques and neurofibrillary tangles
In Parkinson's disease:
- Serum chemokine profiling: XCL1 levels elevated in PD patients compared to healthy controls
- CSF analysis: Altered XCL1 in cerebrospinal fluid, correlating with disease duration
- Genetic association studies: XCL1 and XCR1 polymorphisms associated with PD susceptibility
While primarily a demyelinating disease, MS research provides insights:
- Elevated XCL1 in active lesions and CSF
- Correlation with disability scores
- XCR1+ dendritic cells in inflammatory infiltrates
- Potential for remyelination therapies
¶ Stroke and Ischemia
XCL1 has been studied in cerebral ischemia:
- XCL1 mediates ischemic preconditioning-induced neuroprotection
- Dual role in acute injury and recovery
- Modulation of post-ischemic inflammation
-
XCL1 knockout mice: Used to study the role of XCL1 in neuroinflammation
- Enhanced susceptibility to MPTP-induced parkinsonism
- Altered microglial responses
- Deficient dendritic cell trafficking
-
XCR1 knockout mice: Primary receptor deficiency
- Impaired immune cell recruitment to CNS
- Reduced neuroinflammatory responses
- Altered adaptive immunity
-
Humanized XCL1/XCR1 mice: Transgenic expression of human genes
- Better translational relevance
- Used for drug testing
- 6-OHDA model of PD: XCL1 expression upregulated in substantia nigra
- MPTP model: Chemokine alterations parallel human PD
- APP/PS1 model of AD: XCL1 in amyloid plaque environment
- Aβ injection model: Acute XCL1 response to amyloid
- Transparent CNS for real-time imaging
- Chemokine receptor evolution studies
- Developmental pathways
flowchart LR
A["XCL1 Source"] --> B["XCR1 Receptor"]
B --> C["G Protein Activation"]
C --> D["PLC Activation"]
C --> E["PI3K/Akt"]
C --> F["MAPK/ERK"]
D --> G["Calcium Release"]
D --> H["PKC Activation"]
G --> I["Gene Transcription"]
H --> I
E --> J["Cell Survival"]
F --> K["Proliferation"]
I --> L["Cytokine Production"]
L --> M["Neuroinflammation"]
J --> N["Anti-apoptotic Effects"]
M --> O["Immune Cell Recruitment"]
style A fill:#e1f5fe,stroke:#333
style M fill:#ffcdd2,stroke:#333
style N fill:#c8e6c9,stroke:#333
| Pathway |
Activation |
Neuronal Effect |
| NF-κB |
XCL1 activates NF-κB in microglia |
Pro-inflammatory cytokine production |
| MAPK/ERK |
XCL1 triggers ERK phosphorylation |
Cell survival, proliferation |
| Akt/mTOR |
XCL1 activates Akt signaling |
Metabolic regulation, autophagy |
| JAK/STAT |
Modulated by XCL1 |
Cytokine signaling, immune modulation |
| p38 MAPK |
XCL1 activates p38 |
Stress response, cytokine production |
XCL1 interacts with multiple pathways implicated in neurodegeneration:
| Pathway |
Interaction |
Effect |
| Amyloid processing |
Modulates APP processing |
May influence Aβ production |
| Alpha-synuclein |
Affects aggregation kinetics |
PD-relevant |
| Tau pathology |
Neuroinflammation-mediated |
May accelerate tangles |
| Mitochondrial function |
Alters mitochondrial dynamics |
Energy metabolism |
| Autophagy |
Modulates autophagic flux |
Protein clearance |
| Receptor |
Cell Type |
Function |
| XCR1 |
Dendritic cells, CD8+ T cells |
Primary receptor |
| XCR1 |
Microglia |
Neuroinflammatory signaling |
| XCR1 |
Neurons |
Potential novel signaling |
| Unknown |
Neurons |
Putative alternative receptor |
XCL1 interacts with other chemokines and cytokines:
- CCL2 (MCP-1): Synergistic inflammatory effects
- CXCL8 (IL-8): Coordinated neutrophil recruitment
- TNF-α: Amplified neuroinflammation
- IL-1β: Enhanced microglial activation
- IFN-γ: T cell activation and polarization
- IL-10: Anti-inflammatory modulation
- Amyloid precursor protein (APP): Possible interaction in AD
- Alpha-synuclein: Potential effect on aggregation
- Tau: Neuroinflammation-mediated pathology
- GBA: Lysosomal function in immune cells
- LRRK2: May affect immune cell function
- Single-cell analysis: Understanding XCL1 production at single-cell resolution
- Spatial transcriptomics: Mapping XCL1/XCR1 in brain regions
- Phosphoproteomics: Downstream signaling networks
- CRISPR screening: Identifying novel pathway components
- Biologics: Monoclonal antibodies against XCL1 or XCR1
- Small molecules: Orally bioavailable XCR1 antagonists
- Gene therapy: AAV-mediated modulation of signaling
- Cell therapy: Engineered immune cells with altered XCL1 responses
- CSF XCL1: Diagnostic and prognostic biomarker potential
- Peripheral blood XCR1: Disease progression marker
- Imaging ligands: PET tracers for XCR1 visualization
- Chemokines and neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation, 2019.
- Chemokine dysregulation in Parkinson's disease. Movement Disorders, 2018.
- Crystal structure of lymphotactin. Journal of Biological Chemistry, 2002.
- T cell-mediated immunity in Alzheimer's disease. Nature Reviews Immunology, 2021.
- Dendritic cells in Alzheimer's disease. Brain, 2020.
- The XC chemokine family and its receptor XCR1 in immune regulation. Cytokine & Growth Factor Reviews, 2022.
- Dual role of XCL1 in neuroinflammation: balancing protection and pathology. Journal of Molecular Neuroscience, 2023.
- XCR1 antagonism as a therapeutic strategy for neuroinflammatory disorders. Pharmacological Research, 2024.
- Elevated XCL1 levels in cerebrospinal fluid of Alzheimer's disease patients. Neurological Sciences, 2023.
- Chemokine profiling in rodent models of Parkinson's disease. Neurobiology of Disease, 2022.
- XCL1/XCR1 axis in multiple sclerosis: implications for demyelination and repair. Annals of Neurology, 2021.
- Aging-associated changes in chemokine expression in the brain. Aging Cell, 2020.
- Genetic variants in XCL1 and XCR1 genes and susceptibility to neurodegenerative diseases. Journal of Neurogenetics, 2023.
- XCL1 mediates ischemic preconditioning-induced neuroprotection. Stroke, 2021.
- Autoimmune mechanisms in neurodegenerative disease: the role of chemokines. Nature Reviews Neurology, 2022.
- Targeting the XCL1-XCR1 axis: new therapeutic approaches for neuroinflammation. Expert Opinion on Therapeutic Targets, 2024.
- Peripheral immune dysregulation in Alzheimer's disease: chemokine alterations. Brain, Behavior, and Immunity, 2022.
- Association between chemokine levels and cognitive decline in aging. Neurology, 2023.